NPC-2014-GPOH-Registry

• Continuation of the good results of the trials NPC 1991 and NPC-2003-GPOH
• Ongoing quality warranty by gathering of reference findings and collection of epidemiological data
• Further evaluation of the value of PET-CT in correlation to MRT for the assessment of the remission
• Continuation of the regime to reduce the radiation dose for patients with complete remission after neoadjuvant chemotherapy
• Further evaluation of the value of virological markers
• Collection of biological material (tumour, blood) for the support of essential accompanying scientific studies

Based on the results of the trial NPC-2003 the registry offers a recommendation for the treatment of the nasopharyngeal carcinoma. It corresponds to the state of the art for the treatment of the nasopharyngeal carcinoma

Stadium I: Radiotherapy 45Gy+14,4Gy; followed by off-label Interferon-therapy with Rebif®
Stadium II-IV (M0): Chemotherapy with 3 courses Cisplatin and 5-FU; depending of the response followed by radiotherapy with 45Gy+9,4Gy or 45Gy+14,4 Gy and parallel 2 courses chemotherapy with Cisplatin. Followed by off-label Interferon-therapy with Rebif®
Stadium IV (M1):Chemotherapy with 4 courses Cisplatin and 5-FU; radiation of the primary tumour with 45Gy+14,4Gy and the metatases following the recommendaton of the reference radiologist;, parallel to the radiation 2 courses chemotherapy with Cisplatin and T-Cell-therapy. Followed by off-label Interferon-therapy witht Rebif®

• Primary diagnosis of nasopharyngeal carcinoma
• Histology WHO Type II b or IIIa-b
• Age up to 25 years
• Reefernce histology
• Written consent

• Keratinizing squamous cell carcinoma (WHO Typ I)
• Pretreatment with radio- or chemotherapy
• Secondary malignancy
• Pregnancy
• Missing written informed consent for data transfer